Sirolimus use in recipients of expanded criteria donor kidneys

Drugs

Volumn 68, Issue SUPPL. 1, 2008, Pages 41-49

  House, Andrew A ^a,b,c   Nguan, Christopher Y ^d   Luke, Patrick P ^a,b,c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c Multi Organ Transplant Program (MOTP)   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Renal transplant; Renal transplant rejection, prevention; Sirolimus, therapeutic use

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; CYCLOSPORIN; RAPAMYCIN; TACROLIMUS;

ALGORITHM; CLINICAL PROTOCOL; CREATININE BLOOD LEVEL; EXPANDED CRITERIA DONOR KIDNEY; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; NEPHROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; STANDARDIZATION; VASCULAR DISEASE;

CLINICAL TRIALS AS TOPIC; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; SIROLIMUS; SURVIVAL RATE; TISSUE DONORS; TREATMENT OUTCOME; WAITING LISTS;

EID: 42649106827     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868001-00006     Document Type: Review

References (37)

1. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999 Dec 2; 341 (23): 1725-30
2. Ojo AO, Hanson JA, Meier-Kriesche H, et al. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol 2001 Mar; 12 (3): 589-97
3. Ojo AO. Expanded criteria donors: process and outcomes. Semin Dial 2005 Nov-Dec; 18 (6): 463-8
4. Merion RM, Ashby VB, Wolfe RA, et al. Deceased-donor characteristics and the survival benefit of kidney transplantation. JAMA 2005 Dec 7; 294 (21): 2726-33
5. Port FK, Bragg-Gresham JL, Metzger RA, et al. Donor characteristics associated with reduced graft survival: an approach to expanding the pool of kidney donors. Transplantation 2002 Nov 15; 74 (9): 1281-6
6. Stratta RJ, Rohr MS, Sundberg AK, et al. Intermediate-term outcomes with expanded criteria deceased donors in kidney transplantation: a spectrum or specter of quality? Ann Surg 2006 May; 243 (5): 594-601
7. Tonelli M, Klarenbach S, Manns B, et al., on behalf of the Alberta Kidney Disease Network. Residence location and likelihood of kidney transplantation. CMAJ 2006 Aug 29; 175 (5): 478-82
8. Canadian Organ Replacement Register (CORR), 2005. e-Statistics report on transplant, waiting list and donor statistics. 2005 summary statistics, January 1 to December 31, 2005. Ottawa: The Society, 2005 [online]. Available from URL: http://www.icis.ca/cihiweb/dispPage.jsp?cw_page=reports_corrstats2005c_e [Accessed 2007 Jan 20]
9. Okechukwu CN, Lopes AA, Stack AG, et al. Impact of years of dialysis therapy on mortality risk and the characteristics of longer term dialysis survivors. Am J Kidney Dis 2002 Mar; 39 (3): 533-8
10. Rosengard BR, Feng S, Alfrey EJ, et al. Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor. Am J Transplant 2002 Sep; 2 (8): 701-11
11. Metzger RA, Delmonico FL, Feng S, et al. Expanded criteria donors for kidney transplantation. Am J Transplant 2003; 3 Suppl. 4: 114-25
12. Freeman RB, Klintmalm GB. It is time to re-think 'extended criteria'. Am J Transplant 2006 Oct; 6 (10): 2225-7
13. UNOS, 2006. Organ distribution: allocation of deceased kidneys. UNOS Policy 3.5.1. Definition of expanded criteria donor and standard donor. Richmond (VA): United Network for Organ Sharing, 2006 [online]. Available from URL: http://www.unos.org/policiesandbylaws/policies.asp?.resources = true [Accessed 2007 May 10]
14. Nathan HM, Conrad SL, Held PJ, et al. Organ donation in the United States. Am J Transplant 2003; 3 Suppl. 4: 29-40
15. Scientific Registry of Transplant Recipients (SRTR), 2005. OPTN/SRTR 2005 Annual Report. The U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients [online]. Available from URL: http://www.ustransplant.org/annual_reports/current/default.htm [Accessed 2007 Jan 20]
16. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002 Oct 27; 74 (8): 1070-6
17. Yilmaz S, Sar A. Pathogenesis and management of chronic allograft nephropathy. Drugs 2008; 68 Suppl. 1: 21-31
18. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004 Aug; 4 (8): 1289-95
19. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003 Dec 11; 349 (24): 2326-33
20. Nankivell BJ, Borrows RJ, Fung CL, et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004 Aug 27; 78 (4): 557-65
21. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004 Nov; 4 (11): 1776-85
22. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006 Mar; 6 (3): 514-22
23. Webster AC, Lee VW, Chapman JR, et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006 May 15; 81 (9): 1234-48
24. Meier-Kriesche HU, Srinivas TR, Kaplan B. Interaction between acute rejection and recipient age on long-term renal allograft survival. Transplant Proc 2001 Nov-Dec; 33 (7-8): 3425-6
25. Mekeel K, Meier-Kriesche H-U, Kaplan B. Are we making progress in kidney transplantation? Curr Opin Organ Transplant 2006 Feb; 11 (1): 1-6
26. Meier-Kriesche HU, Schold JD, Gaston RS, et al. Kidneys from deceased donors: maximizing the value of a scarce resource. Am J Transplant 2005 Jul; 5 (7): 1725-30
27. Luke PPW, Nguan CYC, Gregor L, et al. Immunosuppression without calcineurin inhibition in renal transplantation: optimization of renal function in extended donors. In: World Transplant Congress 2006 Oral Abstracts. Am J Transplant 2006 Aug; 6 (s2): 514
28. Whiting JF, Golconda M, Smith R, et al. Economic costs of expanded criteria donors in renal transplantation. Transplantation 1998 Jan 27; 65 (2): 204-7
29. Pfaff WW, Howard RJ, Patton PR, et al. Delayed graft function after renal transplantation. Transplantation 1998 Jan 27; 65 (2): 219-23
30. Brennan DC, and the Thymoglobulin Induction Study Group. Thymoglobulin versus Simulect for induction immunosuppression in cadaveric renal transplant recipients: final results from a prospective, randomized, multicenter trial [abstract no. 1121]. Am J Transplant 2003 May; 3 Suppl. 5: 438
31. Swanson SJ, Hale DA, Mannon RB, et al. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet 2002 Nov 23; 360 (9346): 1662-4
32. Shaffer D, Langone A, Nylander WA, et al. A pilot protocol of a calcineurin-inhibitor free regimen for kidney transplant recipients of marginal donor kidneys or with delayed graft function. Clin Transplant 2003; 17 Suppl. 9: 31-4
33. Furian L, Baldan N, Margani G, et al. Calcineurin inhibitor-free immunosuppression in dual kidney transplantation from elderly donors. Clin Transplant 2007 Jan-Feb; 21 (1): 57-62
34. Cruzado JM, Bestard O, Riera L, et al. Immunosuppression for dual kidney transplantation with marginal organs: the old is better yet. Am J Transplant 2007 Mar; 7 (3): 639-44
35. Re LS, Rial MC, Guardia OE, et al. Results of a calcineurin-inhibitor- free immunosuppressive protocol in renal transplant recipients of expanded criteria deceased donors. Transplant Proc 2006 Dec; 38 (10): 3468-9
36. Pisani F, Buonomo O, Iaria G, et al. Sirolimus in kidney transplantation from marginal donors. Transplantation Proc 2004 Apr; 36 (3): 495-6
37. Matsuoka L, Shah T, Aswad S, et al. Pulsatile perfusion reduces the incidence of delayed graft function in expanded criteria donor kidney transplantation. Am J Transplant 2006 Jun; 6 (6): 1473-8